[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363098-105":59,"doc-detail-363098-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pulmonary-surfactant-protein-d-reduces-lung-cancer-progression-associated-with-decreased-il-4stat6-signaling","Pulmonary surfactant protein D reduces lung cancer progression associated with decreased IL-4/STAT6 signaling","","Pulmonary surfactant protein D (SP-D) is an innate immune molecule linked to lung cancer outcomes, yet the transcriptional programs it controls in cancer progression and metastasis are not fully defined. Integrative multimodal human data show near-absence of SFTPD in metastatic NSCLC, linking loss to metastatic progression. SFTPD overexpression and intranasal SP-D administration reduce tumor growth and metastasis in vivo, suppressing IL-4/STAT6 signaling. Clinical samples associate SFTPD with reduced IL-4/STAT6 activity, and low SFTPD with elevated IL-4 predicts the poorest disease-free survival. These results support SP-D–mediated protection against NSCLC progression via IL-4/STAT6 blockade.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pulmonary-surfactant-protein-d-reduces-lung-cancer-progression-associated-with-decreased-il-4stat6-signaling/363098/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pulmonary-surfactant-protein-d-reduces-lung-cancer-progression-associated-with-decreased-il-4stat6-signaling/363098.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What relationship between SFTPD expression and metastatic NSCLC progression was found?","Question",{"text":112,"@type":113},"SFTPD expression is reduced to near absence in metastatic non-small cell lung cancer tissue, linking its loss to metastatic progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does SFTPD overexpression or SP-D administration affect lung cancer in vivo?",{"text":117,"@type":113},"SFTPD overexpression in A549 lung adenocarcinoma cells and intranasal recombinant SP-D administration both significantly decrease lung tumor growth and metastasis in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling pathway is suppressed by SP-D in this study?",{"text":121,"@type":113},"SP-D suppresses IL-4/STAT6 signaling, and clinical tumor samples show that higher SFTPD expression aligns with reduced IL-4/STAT6 signaling activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363098,1790246246,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","npj | precision oncology Article  \n\n| Published in partnership with The Hormel Institute, University of Minnesota |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41698-025-01163-6](https://doi.org/10.1038/s41698-025-01163-6) |  |  |\n| Pulmonary surfactant protein D reduces lung cancer progression associated with decreased IL-4/STAT6 signaling\u003Cbr> Check for updates |  |  |\n| Ali Mohammadi1, Mohammed Inayatullah1, Anders Schlosser1, Bartosz Pilecki1, Niels Marcussen2, Seyda Ünsal1, Behzad Mansoori1, Behzad Baradaran3, Yousef Tallouzi1, Morten Frier Gjerstorff1,4,5, Jonas Graversen1, Kim Ravnskjær6, Vijay K. Tiwari1, Mikkel G. Terp1,7  & Grith Lykke Sorensen1,7  |  |  |\n| Pulmonary surfactant protein D (SP-D) is an innate immune molecule implicated in lung cancer, where its expression correlates with improved survival and reduced tumor growth. Despite its relevance to lung pathobiology, the transcriptional programs regulated by SP-D and their role in cancer progression and metastasis remain poorly understood. Through integrative analysis of multimodal human data we demonstrate that the SP-D gene (SFTPD) expression is reduced to near absence in metastatic non-small cell lung cancer (NSCLC) tissue, linking its loss to metastatic progression. SFTPD overexpression in A549 lung adenocarcinoma cells signiﬁcantly decreased tumor growth and metastasis in vivo, and intranasal SP-D protein administration reduced lung tumor burden. Mechanistically, SP-D suppressed several signaling pathways, including IL-4/STAT6 signaling. Analysis of clinical lung tumor samples conﬁrmed that SFTPD expression is associated with reduced IL-4/STAT6 signaling, and patients with low SFTPD expression and elevated IL-4 signaling in their tumors showed the poorest disease-free survival. Our ﬁndings demonstrate that SP-D interacts with NSCLC cells to suppress lung cancer progression, in part by blocking of the IL-4/STAT6 signaling pathway. |  |  |\n| Lung cancer is the second most commonly diagnosed cancer and the leading cause ofcancer-related death, with2.5million new cases and1.8million deaths reported in20221,2. According to the latest estimates from the National Center for Health Statistics, approximately 245,000 new cases of lung cancer are expected to be diagnosed in the United States alone in 20253. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising adenocarcinoma, squamous cell carcinoma, andlarge cell carcinoma subtypes. NSCLC accounts for 80-90% of all lung cancer diagnoses, and is frequently diagnosed at the metastatic stage, which is associated with a poor prognosis4. Treatment of NSCLC typically involves a multidisciplinary approach. While surgery and chemotherapy can potentially cure patients with resectable NSCLC, the combination of radiation therapy and chemotherapy has been shown to improve long-term survival in cases with locally advanced, unresectable disease. In cases of advanced metastatic NSCLC, chemotherapy and targeted therapies, guided by molecular characterization of speciﬁc druggable | targets, have demonstrated survival beneﬁt and symptom relief5. Moreover, recent randomized controlled trials have shown that treatment regimens including immune checkpoint inhibitors signiﬁcantly improve survival compared to chemotherapy alone4,6. However, despite these advances, most patients do not respond to immune checkpoint inhibitor-based therapies, and many of those who do initially respond will eventually develop progressive disease. Given these limitations, it is important to investigate how local factors in the lung microenvironment may help protect against cancer progression and whether they can be harnessed to inhibit tumor development and metastasis.\u003Cbr>Pulmonary SP-D is a soluble, calcium-dependent (C-type) lectin, which is primarily synthesized by non-ciliated bronchiolar epithelial cells (Club cells) and alveolar type II cells7,8. SP-D plays multiple roles in pulmonary innate immunity, including pro","cbCainrkHeuwUjd2","https://ap.wps.com/l/cbCainrkHeuwUjd2","pdf",4419075,13,"English","# Background\n## Non-small cell lung cancer and treatment challenges\n## Innate immune roles of SP-D\n# Methods and Integrative Analysis\n## Multimodal human data analysis\n## Experimental modulation of SFTPD/SP-D\n# Results\n## SFTPD loss in metastatic NSCLC\n## SP-D effects on tumor growth and metastasis\n## Mechanistic suppression of IL-4/STAT6 signaling\n## Clinical association with patient outcomes\n# Conclusion","[{\"question\":\"What relationship between SFTPD expression and metastatic NSCLC progression was found?\",\"answer\":\"SFTPD expression is reduced to near absence in metastatic non-small cell lung cancer tissue, linking its loss to metastatic progression.\"},{\"question\":\"How does SFTPD overexpression or SP-D administration affect lung cancer in vivo?\",\"answer\":\"SFTPD overexpression in A549 lung adenocarcinoma cells and intranasal recombinant SP-D administration both significantly decrease lung tumor growth and metastasis in vivo.\"},{\"question\":\"Which signaling pathway is suppressed by SP-D in this study?\",\"answer\":\"SP-D suppresses IL-4/STAT6 signaling, and clinical tumor samples show that higher SFTPD expression aligns with reduced IL-4/STAT6 signaling activity.\"}]","Pulmonary surfactant protein D reduces lung cancer progression associated with decreased IL-4/STAT6 signaling | PDF",1790150027,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16284e9aa4ee65d97d86e03cbe5d524e.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46f1913cfc0f8c60a229a99933ccbc08.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eb9c3a9dea83a17fc46779669daf7d2.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8371900a09ef25502406d1c7a15771a7.webp",980,1301]